ANDA 65375, held by Fresenius Kabi USA. Cefotetan Disodium.
As of Nov 21, 2026, ANDA 65375 (Cefotetan), held by Fresenius Kabi USA, was first approved by FDA on Aug 9, 2007, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 9, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| CefotetanEQ 10GM BASE/VIAL · injectable;injection | Cefotetan Disodium | Discontinued |
| Jan 22, 2013 | Supplement 3Manufacturing | Approved | None posted |
| Aug 9, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters